{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:04:57Z","timestamp":1790301897459,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Otsuka Pharmaceutical Development and Commercialization Inc"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1053\/j.ajkd.2014.11.010","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T18:32:35Z","timestamp":1421346755000},"page":"833-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function"],"prefix":"10.1053","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct01336972","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wendy E.","family":"Boertien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert J.","family":"ter Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco J.","family":"Renken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"van der Jagt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kappert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin E.","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"van Oeveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Struck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Oberdhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly B.","family":"Krasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2014.11.010_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ajkd.2007.10.037","article-title":"Variation in age at ESRD in autosomal dominant polycystic kidney disease","volume":"51","author":"Reed","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2014.11.010_bib2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2014.11.010_bib3","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, cl secretion, and in\u00a0vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1053\/j.ajkd.2014.11.010_bib4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2014.11.010_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of\u00a0autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.ajkd.2014.11.010_bib6","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2014.11.010_bib7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.ajkd.2014.11.010_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2014.11.010_bib9","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2014.11.010_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"10.1053\/j.ajkd.2014.11.010_bib11","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2014.11.010_bib12","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"issue":"8901","key":"10.1053\/j.ajkd.2014.11.010_bib13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ajkd.2014.11.010_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2014.11.010_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"issue":"4","key":"10.1053\/j.ajkd.2014.11.010_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1681\/ASN.V74567","article-title":"Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran","volume":"7","author":"Apperloo","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2014.11.010_bib17","first-page":"97","article-title":"A\u00a0radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow","volume":"20","author":"Donker","year":"1977","journal-title":"Neth J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2014.11.010_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5414\/CNP72337","article-title":"Glomerular filtration rate measurements by 125I-iothalamate should be corrected for inaccurate urine collections with 131I-hippuran","volume":"72","author":"Michels","year":"2009","journal-title":"Clin Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2014.11.010_bib19","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"3","key":"10.1053\/j.ajkd.2014.11.010_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.shk.0000225415.5969694.ce","article-title":"Biomarkers of acute renal injury and renal failure","volume":"26","author":"Trof","year":"2006","journal-title":"Shock"},{"issue":"pt 3","key":"10.1053\/j.ajkd.2014.11.010_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1042\/bj2730759","article-title":"Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization","volume":"273","author":"Maatman","year":"1991","journal-title":"Biochem J"},{"issue":"6","key":"10.1053\/j.ajkd.2014.11.010_bib22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1681\/ASN.V76906","article-title":"Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenic role in interstitial monocytes recruitment","volume":"7","author":"Grandaliano","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2014.11.010_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","article-title":"Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis","volume":"56","author":"Meijer","year":"2010","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614014656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614014656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:32:21Z","timestamp":1759458741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638614014656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0272638614014656"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.11.010","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}